Composition of piper sarmentosum and psidium guajava leaf extract and application of composition in inhibiting mycoplasma
The combination of Pseudoconjuncea oleracea and guava leaf extracts significantly improves the inhibitory activity against porcine mycoplasma, solves the problem of poor prevention and control of porcine mycoplasma pneumonia in the existing technology, and provides a new prevention and control method.
Patent Information
- Application Number
- CN202511163028.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-08-19
- Publication Date
- 2025-10-14
AI Technical Summary
Existing technologies are unable to effectively inhibit porcine mycoplasma pneumonia, which leads to stunted growth of pigs, large-scale infection and even death, and existing prevention and control measures have limited effectiveness.
A combination of Pseudocongmus konjac and guava leaf extracts is used, and by adjusting the mass ratio of the two extracts, a significant additive effect is formed, which significantly improves the inhibitory activity against swine mycoplasma.
It significantly improves the inhibitory effect on Mycoplasma hyopneumoniae, provides new prevention and treatment drug options, and promotes disease prevention and control in the pig breeding process.
Smart Images

Figure CN120771194A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biomedicine, and particularly relates to a composition of extracts of Pseudoconchoe and Psidium guajava leaves and application thereof in inhibiting mycoplasma. Background Art
[0002] Mycoplasma hyopneumoniae is a species of the Mycoplasma family. This pathogen can cause swine pneumonia, a disease characterized by coughing and wheezing in pigs, hence the name "swine panting disease."
[0003] Mycoplasma pneumonia can occur year-round, severely harming pigs at all stages of growth. It can also affect pig growth rates and even cause widespread infection and mortality, significantly impacting the pig farming industry. Currently, comprehensive measures are often required to prevent and control Mycoplasma pneumonia, including vaccination, biosafety, animal husbandry management, and drug prevention and treatment. Therefore, developing effective drugs to inhibit Mycoplasma and improve the prevention and treatment of Mycoplasma pneumonia is of great significance to the pig farming industry. Summary of the Invention
[0004] The present invention provides a composition of extracts of Pseudocongmus jejuni and guava leaves and an application thereof in inhibiting mycoplasma. The combined use of the Pseudocongmus jejuni extract and the guava extract can significantly enhance the mycoplasma inhibitory activity.
[0005] The technical solution of the present invention is achieved as follows:
[0006] A composition for inhibiting mycoplasma, comprising at least one of a Pseudoconjuncea tinctoria extract or a guava leaf extract.
[0007] Furthermore, the mycoplasma inhibiting composition comprises a Pseudoconjuncea tinctoria extract and a guava leaf extract.
[0008] Furthermore, the minimum inhibitory concentration (MIC) of Pseudomonas aeruginosa extract (PSE) against Mycoplasma suis was 0.78125 mg / ml, and the MIC of guava leaf extract (GE) against Mycoplasma suis was 0.390625 mg / ml.
[0009] Furthermore, the FIC of the combined action of PSE and GE on Mycoplasma suis was 0.75, showing an additive effect. At this time, the corresponding mass ratio of Pseudomonas aeruginosa extract and guava leaf extract was 1:1.
[0010] Furthermore, the preparation method of the Pseudocongmus konjac extract is:
[0011] Take dried pseudocones (equal amounts of dried leaves and dried rhizomes), add 60% ethanol and reflux extract for 2 hours, filter to obtain the extract, extract twice in total, combine the extracts and dry them to obtain the product.
[0012] The volume of 60% ethanol added in the first extraction is 6-10 times (v / w) the weight of the pseudocone, and the volume of 60% ethanol added in the second extraction is 6-8 times (v / w) the weight of the pseudocone.
[0013] Furthermore, the preparation method of the guava leaf extract is:
[0014] Take dried guava leaves, add 60% volume concentration of ethanol, soak and reflux extract for 1 hour, filter to obtain the extract, extract twice in total, combine the extracts and dry them to obtain the product.
[0015] The volume of 60% ethanol added in the first extraction is 6-10 times (v / w) the weight of the pseudocone, and the volume of 60% ethanol added in the second extraction is 6-8 times (v / w) the weight of the pseudocone.
[0016] Application of the above composition in inhibiting mycoplasma.
[0017] The application of the above composition in preparing preparations for preventing and treating diseases caused by mycoplasma.
[0018] Furthermore, the mycoplasma is Mycoplasma hyopneumoniae.
[0019] Furthermore, in the application, the concentrations of the Pseudoconjuncea konjac extract and the guava leaf extract are not less than 0.1953125 mg / mL.
[0020] Beneficial effects of the present invention:
[0021] The konjac extract and guava leaf extract of the present invention both have inhibitory activity against Mycoplasma hyopneumoniae, with MICs of 0.78125 mg / ml and 0.390625 mg / ml, respectively. The konjac extract and guava leaf extract are used in combination, and a composition is prepared by adjusting the mass ratio of the two extracts. The inhibitory activity against Mycoplasma hyopneumoniae is significantly improved. The FIC index of the composition of the konjac extract and guava leaf extract alone reaches 0.75, showing a significant additive effect. The above results provide new inhibitory drugs for the prevention and treatment of Mycoplasma hyopneumoniae, and provide new candidate drugs for the comprehensive prevention and treatment of mycoplasmal pneumonia in pig farming, which has important promoting significance for the prevention and treatment of diseases in pig farming. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the embodiments or the description of the prior art. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.
[0023] Figure 1 This is the result of the FIC index determination of the combined effect of PSE and GE on swine mycoplasma using the checkerboard method. The left picture is the picture at the beginning of the experiment, and the right picture is the picture at the end of the experiment. DETAILED DESCRIPTION
[0024] The following will clearly and completely describe the technical solutions in the embodiments of the present invention in conjunction with the accompanying drawings. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. All other embodiments obtained by ordinary technicians in this field based on the embodiments of the present invention without making any creative efforts shall fall within the scope of protection of the present invention.
[0025] Example 1
[0026] 1. Preparation of Pseudoconopsis konjac extract (PSE) and guava leaf extract (GE)
[0027] Preparation of Pseudocongia extract: Take dried Pseudocongia (equal amounts of dried leaves and dried rhizomes), add 60% ethanol and reflux extract for 2 hours, filter to obtain the extract, extract twice in total, combine the extracts and dry them to obtain the extract.
[0028] The volume of 60% ethanol added in the first extraction is 6-10 times (v / w) the weight of the pseudocone, and the volume of 60% ethanol added in the second extraction is 6-8 times (v / w) the weight of the pseudocone.
[0029] Preparation of guava leaf extract: Take dried guava leaves, add 60% volume concentration of ethanol, soak and reflux extract for 1 hour, filter to obtain the extract, extract twice in total, combine the extracts and dry them.
[0030] The volume of 60% ethanol added in the first extraction is 6-10 times (v / w) the weight of the pseudocone, and the volume of 60% ethanol added in the second extraction is 6-8 times (v / w) the weight of the pseudocone.
[0031] Considering the subsequent applications, since the solid-liquid ratio of the first extraction of Pseudocongmus was 1:10 and the second extraction was 1:8, which are more suitable for pilot production, and the solid-liquid ratio of the first extraction of Pseudocongmus was 1:10 and the second extraction was 1:8, which are more suitable for pilot production, the Pseudocongmus extract and Pseudocongmus leaf extract prepared by the above two methods were selected for subsequent experiments.
[0032] 2. Determination of MIC values of Pseudomonas aeruginosa extract (PSE) and guava leaf extract (GE) against mycoplasma
[0033] 1. Mycoplasma hyopneumoniae (J strain), provided by the Veterinary Research Institute of Jiangsu Academy of Agricultural Sciences, was inoculated into KM2 medium to resuscitate the mycoplasma. Its concentration was determined by the color change unit (CCU) method and diluted to 10% with KM2 medium. 4 CCU / ml.
[0034] 2. MIC Determination of PSE and GE
[0035] Pseudoconjuncea sylvestris extract (PSE) and guava leaf extract (GE) were dissolved in 60% ethanol by volume and then diluted with KM2 medium to prepare PSE and GE stock solutions, each at a concentration of 200 mg / mL. The MICs of PSE and GE against mycoplasmas were determined using the doubling dilution method with three replicates. Two controls were set: a drug solution control and a culture medium control. The drug solution control was tiamulin. The stock concentration of tiamulin (TL) was 32 μg / mL.
[0036] Add 100 μl of each of the PSE, GE, and TL stock solutions to the first column of the plate. Add 100 μl of KM2 medium and mix thoroughly. Then, add 100 μl of each to the second column of the plate. Add 100 μl of the diluted mycoplasma solution to column 1 and mix thoroughly. Repeat the above steps for column 2. Set up a total of 12 concentration gradients.
[0037] From well 1 to well 12, the final concentrations of PSE and GE are: 50, 25, 12.5, 6.25, 3.125, 1.5625, 0.78125, 0.390625, 0.1953125, 0.09765625, 0.048828125, and 0.0244140625 mg / mL.
[0038] The final concentrations of tylosin from wells 1 to 12 are: 8, 4, 2, 1, 0.5, 0.25, 0.125, 0.0625, 0.03125, 0.015625, 0.0078125, and 0.00390625 ug / mL.
[0039] After all the hole plates are added, the hole plate is sealed with a sealing film, and is cultured at 37℃ for 10 days. The color change of the solution in each hole is observed by taking a photo every day. The color changes from orange red to yellow or light yellow, indicating that mycoplasma grows. No color change indicates that mycoplasma does not grow.
[0040] The results show that the MIC of GE for Mycoplasma hyopneumoniae is 0.390625 mg / mL, and the MIC of PSE for Mycoplasma hyopneumoniae is 0.78125 mg / mL.
[0041] Example Two
[0042] I. Determination of experimental concentrations of GE and PSE
[0043] According to the MIC value determination results of the single extract in the early stage, the MIC of GE for Mycoplasma hyopneumoniae is 0.390625 mg / mL, and the MIC of PSE for Mycoplasma hyopneumoniae is 0.78125 mg / mL.
[0044] First, the final concentration of the KM2 culture medium containing the extract is determined according to the MIC of the two extracts. Generally, there are eight concentrations, which are 8MIC (i.e. 8 times the MIC concentration, the same below), 4MIC, 2MIC, MIC, 0.5MIC, 0.25MIC, 0.125MIC, and 0.0625MIC.
[0045] Because 50ul of GE and PSE are added at the time of sampling, and the final system is 200ul, in order to ensure that the final concentration of GE and PSE in the system can reach the above eight concentrations, the specific corresponding PSE working solution concentrations to be prepared are: 25 (8MIC), 12.5 (4MIC), 6.25 (2MIC), 3.125 (MIC), 1.5625 (0.5MIC), 0.78125 (0.25MIC), 0.390625 (0.125MIC), and 0.1953125 (0.0625MIC) mg / mL.
[0046] The specific corresponding GE concentrations to be prepared are: 12.5 (8MIC), 6.25 (4MIC), 3.125 (2MIC), 1.5625 (MIC), 0.78125 (0.5MIC), 0.390625 (0.25MIC), 0.1953125 (0.125MIC), and 0.09765625 (0.0625MIC) mg / mL.
[0047] The PSE stock solution and the GE stock solution (200mg / mL) can be diluted by a certain ratio to obtain the above-mentioned concentrations of working solution, and then added in an amount of 50ul per hole to obtain seven final systems of 200ul.
[0048] 2. 2-fold dilution checkerboard assay
[0049] The highest concentration of the extract was 8 times the MIC (4MIC). KM2 culture media containing extracts of various concentrations were mixed in equal amounts in the vertical and horizontal columns of the square array to form a checkerboard pattern of two extract KM2 culture media mixtures with different concentration combinations.
[0050] The calculation formula of the FIC index is: FIC = (MIC of drug A in combination) / (MIC of drug A alone)+(MIC of drug B in combination) / (MIC of drug B alone).
[0051] When FICI≤0.5, the two drugs act synergistically; 0.5 <FICI≤1时,两药作用方式为相加;1<FICI≤2时,两药作用方式为无关;FICI> 2, the two drugs act in an antagonistic manner.
[0052] The operation is as follows: add 50 μL of PSE to each well horizontally, add 50 μL of GE to each well vertically, and finally add 100 μL of KM2 culture medium containing mycoplasma (containing mycoplasma concentration of 10 3 The final volume per well is 200 μL. If mycoplasma growth is observed in every well, it indicates resistance to both drugs, and the FIC cannot be calculated. If mycoplasma growth is not observed in some wells, the lowest concentration combination of PSE and GE drugs that prevents mycoplasma growth must be found. This is the MIC. The FIC is then calculated using the formula, and the interaction is determined based on the above criteria.
[0053] Background control: add 50 μL of PSE drug to each well horizontally, add 50 μL of GE drug to each well vertically, and finally add 100 μL of KM2 medium without mycoplasma to each well (the final volume of each well is 200 μL).
[0054] After 10 days of culture, the color changes were observed. The statistical results are shown in Table 1.
[0055] Table 1 FIC index measurement results
[0056]
[0057] Note: Add 50 μL of PSE to each well horizontally and 50 μL of GE to each well vertically.
[0058] From Table 1 and Figure 1As shown, FIC = 0.5 + 0.25 = 0.75, indicating that the combined effect of GE and PSE is additive. In the final combined system, the lowest concentration of PSE was 0.25 MIC (0.1953125 mg / mL), and the lowest concentration of GE was 0.5 MIC (0.1953125 mg / mL), both of which were significantly lower than the MIC of the individual extracts.
[0059] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.
Claims
1. A composition for inhibiting mycoplasma, characterized in that: Contains at least one of a Pseudocarpus konjac extract or a Psidium guajava leaf extract.
2. The mycoplasma inhibiting composition according to claim 1, characterized in that: The mycoplasma inhibiting composition comprises Pseudomonas aeruginosa extract and Psidium guajava leaf extract.
3. A composition for inhibiting mycoplasma according to claim 1 or 2, characterized in that: The minimum inhibitory concentration of the extract of Pseudocongmus sylvestris against Mycoplasma hyopneumoniae is 0.78125 mg / ml, and the MIC of guava leaf extract against Mycoplasma hyopneumoniae is 0.390625 mg / ml; the FIC of the combined action of Pseudocongmus sylvestris extract and guava leaf extract against Mycoplasma hyopneumoniae is 0.
75.
4. The composition for inhibiting mycoplasma according to claim 1 or 2, characterized in that: The mass ratio of the Pseudoconostoc konjac extract to the guava leaf extract is 1:
1.
5. The composition for inhibiting mycoplasma according to claim 1, wherein: The preparation method of the pseudocone extract is as follows: taking dried pseudocone (equal amounts of dried leaves and dried rhizomes), adding 60% ethanol, reflux extraction for 2 hours, filtering to obtain an extract, extracting twice in total, combining the extracts and drying to obtain the extract; the preparation method of the guava leaf extract is as follows: taking dried guava leaves, adding 60% volume concentration ethanol, soaking them, reflux extraction for 1 hour, filtering to obtain an extract, extracting twice in total, combining the extracts and drying to obtain the extract.
6. The composition for inhibiting mycoplasma according to claim 5, characterized in that: During the preparation of the guava leaf extract and the tiliaceus var. cerevisiae extract, the volume of 60% ethanol added in the first extraction is 6-10 times the weight of the guava leaf extract (v / w), and the volume of 60% ethanol added in the second extraction is 6-8 times the weight of the guava leaf extract (v / w).
7. Use of the composition according to any one of claims 1 to 6 in inhibiting mycoplasma.
8. Use of the composition according to any one of claims 1 to 6 in the preparation of a preparation for preventing and treating diseases caused by mycoplasma.
9. The use according to claim 6 or 7, characterized in that The mycoplasma is Mycoplasma hyopneumoniae.
10. The use according to claim 6 or 7, characterized in that The concentration of the Pseudoconazole extract or the guava leaf extract is not less than 0.1953125 mg / mL.
